NCT00253578View on ClinicalTrials.gov

Sorafenib in Treating Patients With Relapsed or Refractory Multiple Myeloma

PHASE2CompletedINTERVENTIONAL
Enrollment

40

Participants

Timeline

Start Date

March 31, 2006

Primary Completion Date

November 30, 2007

Conditions
Refractory Multiple Myeloma
Interventions
DRUG

sorafenib tosylate

Given PO

OTHER

laboratory biomarker analysis

Correlative studies

Trial Locations (1)

78245

Southwest Oncology Group, San Antonio

All Listed Sponsors
lead

National Cancer Institute (NCI)

NIH

NCT00253578 - Sorafenib in Treating Patients With Relapsed or Refractory Multiple Myeloma | Biotech Hunter | Biotech Hunter